



Attorney Docket No. 041457-0630

#7A
m.m.
10/2/03

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mantelle et al.

Title: Compositions and Methods for Treatment
of Attention Deficit Disorder and Attention
Deficit/Hyperactivity Disorder with
Methylphenidate

Appl. No.: 10/024,513

Filing Date: December 21, 2001

Examiner: Frank I. Choi

Art Unit: 1616

TECH CENTER 1600/2900
OCT 08 2003
RECEIVED

AMENDMENT AND REPLY UNDER 37 CFR § 1.111

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop Non-Fee Amendment
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

This communication is responsive to the Non-Final Office Action dated March 26, 2003, concerning the above-referenced patent application.

The amendments presented below are in compliance with the revised amendment format permitted in the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office dated February 10, 2003, and published at 1267 OG 106 on February 25, 2003. Thus, the provisions of 37 CFR 1.121(a), (b), (c) and (d) are waived for amendments made in this application to the claims, specification, and drawings.

Amendments to the Specification begin on page 3 of this document.

Amendments to the Claims are reflected in the listing of claims which begins on page 4 of this document.

Remarks/Arguments begin on page 9 of this document.

 Please amend the application as follows: